Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CGRP

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Novartis announces new data supporting MS therapy Kesimpta

The latest trial results reinforce the drug's long-term efficacy and safety profile

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links